Summary
This 8-K filing from Bristol Myers Squibb (BMY) reports the outcomes of their Annual Meeting of Shareholders held on May 3, 2022. The primary focus for investors is the shareholder voting results on key corporate governance and compensation matters. Notably, all 10 director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board leadership. The "say-on-pay" advisory vote to approve the compensation of named executive officers also passed with a significant majority, suggesting general shareholder acceptance of the company's executive compensation practices.
Key Highlights
- 1All 10 director nominees were elected to serve until the 2023 Annual Meeting, with high "For" vote counts across the board.
- 2The advisory vote to approve the compensation of named executive officers (say-on-pay) received a substantial majority of "For" votes.
- 3Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2022 with overwhelming support.
- 4A shareholder proposal to lower the ownership threshold for calling special meetings to 10% was not approved.
- 5A shareholder proposal to adopt a Board policy requiring an independent Chairperson was also not approved.